Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30039160 | 1.00 | MAOB (0.51) | MAOBPTGESAPPBCHELMNA | |
| Tetrahydrofuran SCHEMBL28974153 | 0.91 | PTGES (0.43) | MAOBPTGESCCR5 | |
| SCHEMBL1009096 | 0.89 | MAOB (0.51) | MAOBPTGESAPPBCHELMNA | |
| SCHEMBL21218509 | 0.84 | LMNA (0.55) | MAOBBCHELMNACYP1A2PTGS1 | |
| SCHEMBL1010163 | 0.81 | MAOB (0.51) | MAOBPTGESAPPBCHELMNA | |
| SCHEMBL29816877 | 0.81 | MAOB (0.51) | MAOBPTGESAPPBCHELMNA | |
| SCHEMBL14966760 | 0.81 | MAOB (0.49) | MAOB | |
| SCHEMBL11839266 | 0.80 | APP (0.62) | MAOBAPPBCHELMNACYP1A2 | |
| SCHEMBL7471697 | 0.79 | MEN1 (0.46) | MAOB | |
| SCHEMBL19758080 | 0.79 | GSTP1 (0.57) | MAOBPTGESLMNACYP1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110066302-B | Glucopyranosyl derivative and use thereof | 广东东阳光药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-11084842-B2 | Glucopyranosyl derivative and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20210061839-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061839-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SLC5A1, SLC5A2, UGGT1 | MAOB 3915/4885PTGES 1812/4885APP 2335/4885 |
| US-11084842-B2 | Glucopyranosyl derivative and use thereof | SLC5A1, SLC5A2, UGGT1 | MAOB 3915/4885PTGES 1812/4885APP 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.